The FDA decision on bluebird bio Inc.’s (BLUE) investigational gene therapy, Elivaldogene autotemcel, is due on September 16.Elivaldogene autotemcel, or Eli-cel in short, is developed for the treatment of cerebral adrenoleukodystrophy, a rare neurodegenerative disease primarily affecting young children that can lead to progressive, irreversible loss of neurologic function and death.Every year, around 40 persons in the United States are diagnosed with cerebral adrenoleukodystrophy.In June of this year, an FDA panel unanimously backed the approval of Eli-cel for cerebral adrenoleukodystrophy.If approved, Eli-cel will be the first and only gene therapy for the treatment of early active cerebral adrenoleukodystrophy.Eli-cel received regulatory approval in Europe last July and was launched under the brand name Skysona. However, the drug has been withdrawn from the European market due to pricing issues.BLUE closed Friday’s trading at $5.93, down 3.42%.